|
Parameter
|
Progression-free survival
|
Overall survival
|
|---|
|
Hazard ratio (95% CI)
|
p-value
|
Hazard ratio (95% CI)
|
p-value
|
|---|
|
cfDNA level B1 (> median vs ≤ median)
|
3.049 (1.398–6.649)
|
0.005
|
2.236 (1.089–4.590)
|
0.028
|
|
CA 19-9 (< 37U/mL vs ≥ 37U/mL)
| |
n.s.
|
0.345 (0.148–0.804)
|
0.014
|
|
ECOG performance status
| |
0.043
| |
0.011
|
|
0
|
Reference
| |
Reference
| |
|
1
|
1.122 (0.486–2.589)
| |
1.149 (0.540–2.446)
| |
|
2
|
3.108 (1.066–9.056)
| |
4.066 (1.443–11.461)
| |
|
First line treatment
| |
0.003
| |
< 0.001
|
|
FOLFIRINOX
|
Reference
| |
Reference
| |
|
Gemcitabine
|
7.765 (2.313–26.068)
| |
12.064 (3.385–42.996)
| |
|
Nab-Pac + gemcitabine
|
2.021 (1.002–4.076)
| |
2.901 (1.411–5.965)
| |
